Эпилепсия, ассоциированная с менингиомами головного мозга

Данная статья посвящена основным вопросам, касающимся развития эпилептических приступов у пациентов с менингиомами головного мозга. Раскрыты генетические аспекты, связанные с формированием менингиомы у больных, и особенности локализации и степени злокачественности опухоли при каждой отдельной геномной подгруппе. Названы также факторы, играющие главную роль в возникновении преди послеоперационных эпилептических приступов. Хирургическая резекция менингиом на данный момент остается решающим фактором в излечении пациентов от инвалидизирующих симптомов. Но также важной темой, затронутой в данной статье, является необходимость в дальнейшем исследовании особенностей назначения противоэпилептической терапии пациентам в пред- и послеоперационном периодах, которые в основном заключаются в правильном установлении дозировки и сроков приема препаратов, что может изменить представление об эффективности купирования эпилептических приступов.

1. Ahmed RE, Tang H, Asemota A, et al. Meningioma Related Epilepsy- Pathophysiology, Pre/postoperative Seizures Predicators and Treatment J Front. Oncol. 2022: 12. https://doi:10.3389/fonc.2022.905976.

2. Buerki RA, Horbinski CM, Kruser T, et al. An overview of meningiomas. J Future Oncology. 2018;14(21):2161–2177. https://doi:10.2217/fon-2018-0006.

3. Englot DJ, Magill ST, Han SJ, et al. Seizures in supratentorial meningioma: a systematic review and metaanalysis. J Neurosurg. 2016 Jun;124(6):1552–61. https://doi:10.3171/2015.4.JNS142742. Epub. 2015 Dec 4.

4. Taphoorn MJ, Klein M. Cognitive deficits in adult patients with brain tumours. Lancet Neurol. 2004. https://doi.org/10.1016/S1474-4422(04)00680-5

5. van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol. 2007. https://doi:10.1016/S1474-4422(07)70103-5.

6. Jacoby A, Wang W, Vu TD, et al. Meanings of epilepsy in its sociocultural context and implications for stigma: findings from ethnographic studies in local communities in China and Vietnam. EpilepsyBehav. 2008.12(2):286–97. https://doi: 10.1016/j.yebeh.2007.10.006.

7. Chaichana KL, Parker SL, Olivi A, et al. Longterm seizure outcomes in adult patients undergoing primary resection of malignant brain astrocytomas Clinical article. J Neurosurg. 2009. 111(2):282–92. https://doi:10.3171/2009.2.JNS081132.

8. Ruda` R, Trevisan E, Soffietti R, et al. Epilepsy and brain tumors. Curr Opin Oncol. 2010;22(6):611–20. https://doi:10.1097/CCO.0b013e32833de99d.

9. Sizoo EM, Braam L, Postma TJ, et al. Symptoms and problems in the end-of-life phase of high-grade glioma patients. NeuroOncol. 2010.12(11):1162–6. https://doi:10.1093/neuonc/nop045. Epub 2010 Jan 27.

10. Harwards S-C, Rolston J-D, Englot D-J, et al. Seizures in meningioma. J Handbook of Clinical Neurology. 2020:170:187–200. https://doi:10.1016/B978-0-12-822198-3.00053-7.

11. Clark VE, Erson-Omay EZ, Serin A, et al. Genomic Analysis of Non-NF2 Meningiomas Reveals Mutations in TRAF7, KLF4, AKT1, and SMO. Jay Cooke, Private Banker. 2014;339 (March):1077–1081. https://doi:10.1126/science.1233009. Epub 2013 Jan 24.

12. Gupte TP, Li C, Jin L, et al. Clinical and genomic factors associated with seizures in meningiomas. J Neurosurg. 2020;35(3):835–844. https://doi: 10.3171/2020.7.JNS201042.

13. Lieu AS, Howng SL, et al. Intracranial meningiomas and epilepsy: incidence, prognosis and influencing factors. Epilepsy Res. 2000;38(1):45–52. https://doi: 10.1016/s0920-1211(99)00066-2.

14. Chen WC, Magill ST, Englot DJ, et al. Factors associated with pre- and postoperative seizures in 1033 patients undergoing supratentorial meningioma resection. Neurosurgery. 2017;(81):297–306. https://doi:10.1093/neuros/nyx001.

15. Baumgarten P, Sarlak M, Baumgarten G, et al. Focused review on seizures caused by meningiomas. Epilepsy Behav. 2018;88:146–151. https://doi: 10.1016/j.yebeh.2018.09.002.

16. Chozick BS, Reinert SE, Greenblatt SH. Incidence of seizures after surgery for supratentorial meningiomas: a modern analysis. J Neurosurg. 1996(84):382–386. https://doi: 10.3171/jns.1996.84.3.0382.

17. Chow SY, Hsi MS, Tang LM, et al. Epilepsy and intracranial meningiomas. Chin Med J, Free China. 1995;(55):151–155.

18. Hebert AM, DuBoff B, Casaletto JB, et al. Merlin/ERM proteins establish cortical asymmetry and centrosome position. J GenesDev. 2012;26:2709–2723. https://doi: 10.1101/gad.194027.112.

19. Linsler S, Kraemer D, Driess C, et al. Molecular Biological Determinations of Meningioma Progression and Recurrence. PLoS ONE. 2014; 9(4):1–8. https://doi.org/10.1371/journal.pone.0094987

20. van Diessen E, Diederen SJ, Braun KP, et al. Functional and Structural Brain Networks in Epilepsy: What Have We Learned? Epilepsia. 2013;54(11):1855–65. https://doi: 10.1111/epi.12350.

21. Mehta N, Bhagwati S, Parulekar G. Meningiomas in Children: A Study of 18 Cases. J PediatrNeurosci. 2009;4(2):61–5. https://doi: 10.4103/1817-1745.57322.

22. Smith MJ, et al. Germline and somatic mutations in meningiomas. J Cancer Genet. 2015;208(4):107–114. https://doi: 10.1016/j.cancergen.2015.02.003.

23. Sievers P, Sill M, Blume C, et al. Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1. J ActaNeuropathol. 2021;141(2):281–290. https://doi:10.1007/s00401-020-02247-2.

24. Harmanci AS, Youngblood MW, Clark VE, et al. Integrated genomic analyses of de novo pathways underlying atypical meningiomas. J NatCommun. 2017;8:14433. https://doi: 10.1038/ncomms14433.

25. Fiorentini E, Giunti L, Rita A, et al. SMARCE1-related meningiomas: A clear example of cancer predisposing syndrome. European Journal of Medical Genetics. 2023;66(7). https://doi: 10.1016/j.ejmg.2023.104784.

26. Clark VE, Harmancı AS, Bai H, et al. Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas. J Nature Genetics. 2016;48(10):1253–1259. https://doi: 10.1038/ng.3651.

27. Okano A, Miyawaki S, Hongo H, et al. Associations of pathological diagnosis and genetic abnormalities in meningiomas with the embryological origins of the meninges. J Scientific Reports. 2021;11(1):6987. https://doi: 10.1038/s41598-021-86298-9.

28. Clark VE, Erson-Omay EZ, Serin A, et al. Genomic Analysis of Non-NF2 Meningiomas Reveals Mutations in TRAF7, KLF4, AKT1, and SMO. JayCooke, Private Banker. 2014;339 (March):1077–1081. https://doi:10.1126/science.1233009.

29. Sablina A, Najm P, Zhao P, et al. Loss of TRAF7 and KLF4 cooperate to activate the RAS-like GTPase signaling and promote meningioma. Department ofOncology. 2021;81(16):4218–4229. https://doi: 10.1158/0008-5472. CAN-20-3669.

30. Proctor DT, Ramachandran S, Lama S, et al. Towards Molecular Classification of Meningioma: Evolving Treatment and Diagnostic Paradigms. World Neurosurgery. 2018;119:366–373. https://doi:10.1016/j.wneu.2018.08.019.

31. Evans PM, Liu C. Roles of Krüppel‐like factor 4 in normal homeostasis, cancer and stem cells. J Acta Biochimica et BiophysicaSinica. 2008;40(7):554–64. https://doi: 10.1111/j.1745-7270.2008.00439.x.

32. Gamper AM, Qiao X, Kim J, et al. Regulation of KLF4 turnover reveals an unexpected tissue-specific role of pVHL in tumorigenesis. J Mol Cell. 2012;45:233–243. https://doi: 10.1016/j.molcel.2011.11.031.

33. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. J Cell. 2007;131:861–872. https://doi:10.1016/j.cell.2007.11.019.

34. Tang HL, Zhu HD, Wang XC, et al. KLF4 is a tumor suppressor in anaplastic meningioma stem-like cells and human meningiomas. J Mol Cell Biol. 2017;9:315–324. https://doi: 10.1093/jmcb/mjx023.

35. Reuss DE, Piro RM, Jones DTW, et al. Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. J ActaNeuropathol. 2013;125:351–358. https://doi: 10.1007/s00401-013-1093-x.

36. Regelsberger J, Hagel C, Emami P, et al. Secretory meningiomas: a benign subgroup causing life-threatening complications. J Neuro-Oncology. 2009;11:819–824. https://doi: 10.1215/15228517-2008-109.

37. Patil CG, Veeravagu A, Lad SP, et al. Craniotomy for resection of meningioma in the elderly: a multicentre, prospective analysis from the National Surgical Quality Improvement Program. J Neurol Neurosurg Psychiatry 2010;81:502–505. https://doi:10.1136/jnnp.2009.185074.

38. Spreckelsen N, Waldt N, Poetschke R, et al. KLF4K409Q–mutated meningiomas show enhanced hypoxia signaling and respond to mTORC1 inhibitor treatment. J Acta Neuropatholodica Communications 2020.(41). https://doi.org/10.1186/s40478-020-00912-x.

39. Coy S, Rashid R, Stemmer-Rachamimov A, et al. An update on the CNS manifestations of neurofibromatosis type 2 [Internet]. ActaNeuropathol. 2020;139:643–65. https://doi: 10.1007/s00401-019-02029-5.

40. Zhang C, Wang Y, Wang X, et al. Sporadic meningioangiomatosis with and without meningioma: analysis of clinical differences and risk factors for poor seizure outcomes. ActaNeurochir. 2015;157:841–53. https://doi: 10.1007/s00701-015-2375-y.

41. Kim NR, Choe G, Shin SH, et al. Childhood meningiomas associated with meningioangiomatosis: Report of five cases and literature review. Neuropathol. ApplNeurobiol. 2002;28:48–56. https://doi:10.1046/j.1365-2990.2002.00365.x.

42. Perry A, Kurtkaya-Yapicier Ö, Scheithauer BW, et al. Insights into meningioangiomatosis with without meningioma: A clinicopathologic end genetic series of 24 cases with review of the literature. BrainPathol. 2005;15:55–65. https://doi: 10.1111/j.1750-3639.2005.tb00100.x.

43. Kim NR, Cho SJ, Suh YL. Allelic loss on chromosomes 1p32, 9p21, 13q14, 16q22, 17p, and 22q12 in meningiomas associated with meningioangiomatosis and pure meningioangiomatosis. J Neurooncol. 2009;94:425–30. https://doi:10.1007/s11060-009-9879-3.

44. Yazaki T, Manz HJ, Rabkin SD, Martuza RL. Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res. 1995;55:4752–6.

45. Zhao L, Zhao W, Hou Y, et al. An Overview of Managements in Meningiomas. J Neuro-Oncology and Neurosurgical Oncology 2020;10:1523. https://doi:10.3389/fonc.2020.01523.

46. Chaichana KL, Pendleton C, Zaidi H, et al. Seizure control for patients undergoing meningioma s urgery. World Neurosurg. 2013;79(3–4):515–24. https://doi:10.1016/j.wneu.2012.02.051.

47. Ferrante L, Acqui M, Artico M, et al. Cerebral meningiomas in children. Childs Nerv Syst. 1989;(5):83–86.

48. Wiemels J, Wrensch M, Claus EB. Epidemiology and etiology of meningioma. J. Neurooncol. 2010;99(3):307–314.

49. Kotsopoulos IA, van Merode T, Kessels FG, et al. Systematic review and meta-analysis of incidence studies of epilepsy and unprovoked seizures. Epilepsia. 2002;(43):1402–1409. https://doi: 10.1007/BF00571115.

50. Hamasaki T, Yamada K, Yano S, et al. Higher incidence of epilepsy in meningiomas located on the premotor cortex: a voxel-wise statistical analysis. Acta Neurochir. 2012;(154): 2241–2249. https://doi:10.1007/s00701-012-1511-1

51. Hamasaki T, Yamada K, Kuratsu J-i. Seizures as a presenting symptom in neurosurgical patients: a retrospective single-institution analysis. Clin Neurol Neurosurg. 115: 2336–2340. 2013. https://doi: 10.1016/j.clineuro.2013.08.016.

52. Bogdanovic I, Ristic A, Ilic R, et al. Factors associated with preoperative and early and late postoperative seizures in patients with supratentorial meningiomas. Epileptic Disord. 2023 Apr;25(2):244–254. DOI: 10.1002/epd2.20021. Epub 2023 May 6. PMID:36939715.

53. Pistolesi S, Fontanini G, Camacci T, et al. Meningioma-associated brain oedema: the role of angiogenic factors and pial blood supply. J Neurooncol. 2002;(60):159–164. https://doi:10.1023/a:1020624119944.

54. Kim OJ, Yong Ahn J, Chung YS, et al. Significance of chronic epilepsy in glial tumors and correlation with surgical strategies/ J Clin Neurosci. 1990.11(7):702–5. https://doi: 10.1016/j.jocn.2003.09.018.

55. Haglund MM, Berger MS, Kunkel DD, et al. Changes in gamma-aminobutyric acid and somatostatin in epileptic cortex associated with low-grade gliomas. J Neurosurg. 1992;(77):209–216. https://doi: 10.3171/jns.1992.77.2.0209.

56. Kawaguchi T, Kameyama S, Tanaka R. Peritumoral edema and seizure in patients with cerebral convexity and parasagittal meningiomas. Neurol Med Chir. 1996;36(8):568–73. https://doi:10.2176/nmc.36.568.

57. Lobato RD, Alday R, Gomez PA, et al. Brain oedema in patients with intracranial meningioma. Correlation between clinical, radiological, and histological factors and the presence and intensity of oedema. ActaNeurochir. 1996;138(5):485–93; discussion 493–4. https://doi: 10.1007/BF01411166.

58. Simis A, Pires de Aguiar PH, Leite CC, et al. Peritumoral brain edema in benign meningiomas: correlation with clinical, radiologic, and surgical factors and possible role on recurrence. Surg Neurol. 2008;70(5):471–7; discussion 477. https://doi:10.1016/j.surneu.2008.03.006.

59. Shamji MF, Fric-Shamji EC, Benoit BG. Brain tumors and epilepsy: pathophysiology of peritumoral changes. Neurosurg Rev. 2009 Jul;32(3):275–84; discussion 284–6. https://doi: 10.1007/s10143-009-0191-7.

60. Ruda` R, Trevisan E, Soffietti R, et al. Epilepsy and brain tumors. Curr Opin Oncol. 2010 Nov;22(6):611–20. https://doi:10.1097/CCO.0b013e32833de99d.

61. Chan PH, Fishman RA, Lee JL, et al. Effects of excitatory neurotransmitter amino acids on swelling of rat brain cortical slices. J Neurochem. 1979 Dec;33(6):1309–15. https://doi: 10.1111/j.1471-4159.1979.tb05278.x.

62. Fishman RA, Chan PH, et al. Metabolic basis of brain edema. AdvNeurol. 1980:28:207–15.

63. Yuen TI, Morokoff AP, Bjorksten A, et al. Glutamate is associated with a higher risk of seizures in patients with gliomas. Neurology. 2012 Aug 28;79(9):883–9. https://doi: 10.1212/WNL.0b013e318266fa89.

64. Yoshioka H, Hama S, Taniguchi E, et al. Peritumoral brain edema associated with meningioma: influence of vascular endothelial growth factor expression and vascular blood supply. Cancer. 1999 Feb 15;85(4):936–44. https://doi: 10.1002/(sici)1097-0142 (19990215)85:4<936::aid-cncr23>3.0.co;2-j.

65. Nordqvist AC, Smurawa H, Mathiesen T. Expression of matrix metalloproteinases 2 and 9 in meningiomas associated with different degrees of brain invasiveness and edema. JNeurosurg. 2001 Nov;95(5):839–44. https://doi: 10.3171/jns.2001.95.5.0839.

66. Ng WH, Hy JW, Tan WL, et al. Aquaporin-4 expression is increased in edematous meningiomas. J ClinNeurosci. 2009 Mar;16(3):441–3. https://doi:10.1016/j.jocn.2008.04.028.

67. Murakoshi H, Wang H, Yasuda R. Local, persistent activation of Rho GTPases during plasticity of single dendritic spines. Nature. 2011 Apr 7;472(7341):100–4. https://doi: 10.1038/nature09823.

68. Iwado E, Ichikawa T, Kosaka H, et al. Role of VEGF and matrix metalloproteinase-9 in peritumoral brain edema associated with supratentorial benign meningiomas. Neuropathology. 2012 Dec;32(6):638–46. https://doi: 10.1111/j.1440-1789.2012.01312.x.

69. Lambertz N, Hindy NE, Adler C, et al. Expression of aquaporin 5 and the AQP5 polymorphism A (-1364) C in association with peritumoral brain edema in meningioma patients. J Neurooncol. 2013 Apr;112(2):297–305. https://doi: 10.1007/s11060-013-1064-z.

70. Nassehi D, et al. Intracranial meningiomas, the VEGF-A pathway, and peritumoral brain oedema. DanMed J. 2013 Apr;60(4):B4626.

71. Fried I, Kim JH, Spencer DD. Limbic and neocortical gliomas associated with intractable seizures: a distinct clinicopathological group. Neurosurgery. 1994 May;34(5):815–23; discussion 823–4. https://doi:10.1227/00006123-199405000-00005.

72. Liigant A, Haldre S, Oun A, et al. Seizure disorders in patients with brain tumors. EurNeurol. 2001;45:46–50. https://doi: 10.1159/000052089.

73. Lynam LM, Lyons MK, Drazkowski JF, et al. Frequency of seizures in patients with newly diagnosed brain tumors: a retrospective review. ClinNeurol Neurosurg. 2007 Sep;109(7):634–8. https://doi:10.1016/j.clineuro.2007.05.017.

74. Lee JW, Wen PY, Hurwitz S, et al. Morphological characteristics of brain tumors causing seizures. Arch Neurol. 2010 Mar;67(3):336–42. https://doi: 10.1001/archneurol.2010.2.

75. Engel J, Bragin A, Staba R, et al. High-frequency oscillations: what is normal and what is not? Epilepsia. 2009 Apr;50(4):598–604. https://doi: 10.1111/j.1528-1167.2008.01917.x.

76. Kukanov KK, Ushanov VV, Zabrodskaya YuM, et al. Ways to personalize the treatment of patients with recurrent and continued growth of intracranial meningiomas. Russian Journal of Personalized Medicine. 2023;3(3):48–63. In Russian [Куканов К.К., Ушанов В.В., Забродская Ю.М. и др. Пути персонификации лечения пациентов с рецидивом и продолженным ростом интракраниальных менингиом. Российский журнал персонализированной медицины. 2023;3(3):48–63]. https://doi.org/10.18705/2782-38062023-3-3-48-63.

77. Watts J, Box G, Galvin A, et al. Magnetic resonance imaging of meningiomas: a pictorial review. InsightsImaging. 2014;5(1):113–122. https://doi: 10.1007/s13244-013-0302-4.

78. Rutten I, Cabay J-E, Withofs N, et al. PET/CT of skull base meningiomas using 2-18F-fluoro-Ltyrosine: initial report. J. Nucl. Med. 2007;48(5):720–725. https://doi:10.2967/ jnumed.106.038216.

79. Rachinger W, Stoecklein VM, Terpolilli NA, et al. Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue. J. Nuc. Med. 2015;56(3):347–353. https://doi: 10.2967/jnumed.114.149120.

80. Afshar-Oromieh A, Wolf MB, Kratochwil C, et al. Comparison of 68Ga-DOTATOC-PET/CT and PET/MRI hybrid systems in patients with cranial meningioma: initial results. Neuro-oncology. 2015;17(2):312–319. https://doi: 10.1093/neuonc/nou131.

81. Bosnyak E, Kamson DO, Guastella AR, et al. Molecular imaging correlates of tryptophan metabolism via the kynurenine pathway in human meningiomas. Neuro-oncology. 2015;17(9):1284–1292. https://doi:10.1093/neuonc/nov098.

82. Benbadis SR, Beniczky S, Bertram E, et al. The role of EEG in patients with suspected epilepsy. Seminar in Epileptology. 2020 Apr 1;22(2):143–155. https://doi:10.1684/epd.2020.1151.

83. Tatum WO, Rubboli G, Kaplan PW, et al. Clinical utility of EEG in diagnosing and monitoring epilepsy in adults. ClinNeurophysiol. 2018 May;129(5):1056–1082. https://doi: 10.1016/j.clinph.2018.01.019.

84. Zada G, Başkaya MK, Shah MV. Introduction: surgical management of skull base meningiomas. Neurosurg. Focus. 2017 Oct;43(VideoSuppl2): Intro. https://doi: 10.3171/2017.10.FocusVid.Intro.

85. Peart R, Melnick K, Cibula J, et al. Clinical management of seizures in patients withmeningiomas: Efficacy of surgical resection for seizure control and patient-tailoredpostoperative anti-epileptic drug management. Neurooncol Adv. 2023 Jun 3;5(Suppl 1):i58–i66. https://doi: 10.1093/noajnl/vdac136.

86. Englot DJ, Berger MS, Barbaro NM, et al. Factors associated with seizure freedom in the surgical resection of glioneuronal tumors. Epilepsia. 2012 Jan;53(1):51–7. https://doi: 10.1111/j.1528-1167.2011.03269.x.

87. Oya S, Kawai K, Nakatomi H, Saito N. Significance of Simpson grading system in modern meningioma surgery: integration of the grade with MIB-1 labeling index as a key to predict the recurrence of WHO grade I meningiomas. J. Neurosurg. 2012;117(1):121–128. https://doi: 10.3171/2012.3.JNS111945.

88. Ramamurthi B, Ravi B, Ramachandran. Convulsions with meningiomas: incidence and significance. SurgNeurol. 1980 (14):415–416.

89. Sun SQ, Hawasli AH, Huang J, et al. An evidencebased treatment algorithm for the management of WHO grade II and III meningiomas. Neurosurg. Focus. 2015;38(3):1–11. https://doi: 10.3171/2015.1.FOCUS14757.

90. Jooma R, Yeh HS, Privitera MD, et al. Lesionectomy versus electrophysiologically guided resection for temporal lobe tumors manifesting with complex partial seizures. J Neurosurg. 1995;83:231–236. https://doi: 10.3171/jns.1995.83.2.0231.

91. Bilginer B, Yalnizoglu D, Soylemezoglu F, et al. Surgery for epilepsy in children with dysembryoplastic neuroepithelial tumor: clinical spectrum, seizure outcome, neuroradiology, and pathology. ChildsNerv. Syst. 2009;25:485–491. https://doi: 10.1007/s00381-008-0762-x.

92. Giulioni M, Rubboli G, Marucci G, et al. Seizure outcome of epilepsy surgery in focal epilepsies associated with temporomesial glioneuronal tumors: lesionectomy compared with tailored resection. J Neurosurg. 2009;(111):1275–1282. https://doi:10.3171/2009.3.JNS 081350.

93. Walcott BP, Nahed BV, Brastianos PK, Loeffler JS. Radiation treatment for WHO grade II and III meningiomas. Front. Oncol. 2013;(3):227. https://doi: 10.3389/fonc.2013.00227.

94. Pollock BE, Stafford SL, Link MJ, et al. Stereotactic radiosurgery of World Health Organization grade II and III intracranial meningiomas: treatment results on the basis of a 22-year experience. Cancer. 2012;118(4):1048–1054. https://doi: 10.1002/cncr.26362.

95. Sheehan JP, Cohen-Inbar O, Ruangkanchanasetr R, et al. Post-radiosurgical edema associated with parasagittal and parafalcine meningiomas: a multicenter study. J. Neurooncol. 2015;125(2):317–324. https://doi: 10.1007/s11060-015-1911-1.

96. Sheehan JP, Starke RM, Kano H, et al. Gamma Knife radiosurgery for posterior fossa meningiomas: a multicenter study. J. Neurosurg. 2015;122(6):1479–1489. https://doi: 10.3171/2014.10.JNS14139.

97. Aghi MK, Carter BS, Cosgrove GR, et al. Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation. Neurosurgery. 2009;64(1):56–60. https://doi: 10.1227/01.NEU.0000330399.55586.63.

98. Komotar RJ, Iorgulescu JB, Raper DMS, et al. The role of radiotherapy following gross-total resection of atypical meningiomas. J. Neurosurg. 2012;117(4):679–68. https://doi: 10.3171/2012.7.JNS112113.

99. Dziuk TW, Woo S, Butler EB, et al. Malignant meningioma: an indication for initial aggressive surgery and adjuvant radiotherapy. J. Neurooncol. 1998;37(2):177–188. https://doi: 10.1023/a:1005853720926.

100. Goldbrunner R, Minniti G, Preusser M, et al. EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol. 2016;17(9):e383–e391. https://doi.org/10.1016/S1470-2045(16)30321-7)

101. Tang Y, Li Y, Luo D, et al. Epilepsy related to radiotherapy in patients with nasopharyngeal carcinoma. Epilepsy Res. 2011 Sep;96(1–2):24–8. https://doi: 10.1016/j.eplepsyres.2011.04.010.

102. Grewal J, Grewal HK, Forman AD, et al. Seizures and epilepsy in cancer: etiologies, evaluation, and management. J CurrOncolRep. 2008 Jan;10(1):63–71. https://doi: 10.1007/s11912-008-0010-2.

103. van Breemen MSM, Rijsman RM, Taphoorn MJB, et al. Efficacy of anti-epileptic drugs in patients with gliomas and seizures. J Neurol. 2009 Sep;256(9):1519–26. https://doi: 10.1007/s00415-009-5156-9.

104. Smart D. Radiation toxicity in the central nervous system: mechanisms and strategies for injury reduction. J Semin Radiat Oncol. 2017 Oct;27(4):332–339. https://doi: 10.1016/j.semradonc.2017.04.006.

105. Hwang K, Kim DG, Paek SH, et al. Seizures After Stereotactic Radiosurgery for Benign Supratentorial Meningiomas: An Uncontrollable Type of Seizure? J World Neurosurgery. 2019 Mar: 123:e549-e556. https://doi: 10.1016/j.wneu.2018.11.211.

106. Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;54:1886–1893. https://doi:10.1212/wnl.54.10.1886.

107. Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNSEANO* Task Force. Eur. J Neurol. 2010;17:1124–1133. https://doi: 10.1111/j.1468-1331.2010.03151.x.

108. Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013; 54:551–563. https://doi: 10.1111/epi.12074.

109. Helmstaedter C, Witt J-A. The effects of levetiracetam on cognition: a non-interventional surveillance study. Epilepsyand Behavior. 2008 Nov;13(4):642–9. https://doi: 10.1016/j.yebeh.2008.07.012.

110. de Groot M, Douw L, Sizoo EM, et al. Levetiracetam improves verbal memory in high-grade glioma patients. NeuroOncol. 2013;15:216–223. https://doi:10.1093/neuonc/nos288.

111. Englot DJ, Chang EF, Vecht CJ, et al. Epilepsy and brain tumors. J Handbook of Clinical Neurology. 2016:134:267–85. https://doi: 10.1016/B978-0-12-802997-8.00016-5.

112. Tinchon A, Oberndorfer S, Marosi C, et al. Haematological toxicity of Valproic acid compared to Levetiracetam in patients with glioblastoma multiforme undergoing concomitant radio-chemotherapy: a retrospective cohort study. J Neurol. 2015;(262):179–186. https://doi: 10.1007/s00415-014-7552-z.

113. Bourg V, Lebrun C, Chichmanian RM, et al. Nitrosourea-cisplatin-based chemotherapy associated with valproate: Increase of haematologic toxicity. Ann. Oncol. 2001;(12):217–219. https://doi:10.1023/a:1008331708395.

114. Simo M, Velasco R, Graus F, et al. Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients treated with standard chemoradiotherapy. J Neurooncol. 2012 Jul;108(3):451–8. https://doi: 10.1007/s11060-012-0836-1.

115. Bénit CP, Vecht CJ. Seizures and cancer: drug interactions of anticonvulsants with chemotherapeutic agents, tyrosine kinase inhibitors and glucocorticoids. NeuroOncolPract. 2016 Dec;3(4):245–260. https://doi:10.1093/nop/npv038.

116. Kaal EC, Vecht CJ. The management of brain edema in brain tumors. CurrOpin Oncol. 2004 Nov;16(6):593–600. https://doi: 10.1097/01.cco.0000142076.52721.b3.

117. French JA, Faught E, et al. Rational polytherapy. Epilepsia. 2009;(50):63–68. https://doi: 10.1111/j.1528-1167.2009.02238.x.

118. Brodie MJ, Sills GJ. Combining antiepileptic drugs-Rational polytherapy? SeizureEuropean Journal of Epilepsy. 2011 Jun; 20(5):369–75. https://doi:10.1016/j.seizure.2011. 01.004.

119. Otoul C, Arrigo C, van Rijckevorsel K, et al. Metaanalysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy. Clin Neuropharmacol. 2005;28(2):72–8. https://doi:10.1097/01.wnf.00001 59956.87511.67.

120. Bodalia PN, Grosso AM, Sofat R, et al. Comparative efficacy and tolerability of anti-epileptic drugs for refractory focal epilepsy: systematic review and network meta-analysis reveals the need for long term comparator trials. Br J ClinPharmacol. 2013;76: 649–667. https://doi: 10.1111/bcp.12083.

121. Kerkhof M, Dielemans JCM, van Breemen MS, et al. Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. NeuroOncol. 2013 Jul;15(7):961–7. https://doi: 10.1093/neuonc/not057.

122. Brodie MJ, Yuen AW. Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group. Epilepsy Res. 1997 Mar;26(3):423–32. https://doi: 10.1016/s0920-1211(96)01007-8.

123. Saria MG, Corle C, Hu J, et al. Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors. J Neurosurg. 2013;(118):1183–1187. https://doi: 10.3171/2013.1.JNS12397.

124. Maschio M, Dinapoli L, Sperati F, et al. Oxcarbazepine monotherapy in patients with brain tumor-related epilepsy: open-label pilot study for assessing the efficacy, tolerability and impact on quality of life. J Neurooncol. 2012a. 2012 Feb;106(3):651–6. https://doi: 10.1007/s11060-011-0689-z.

125. Marson AG, Al-Kharusi AM, Alwaidh M, et al. SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. 2007 Mar 24;369(9566):1000–15. https://doi:10.1016/S0140-6736(07)60460-7.

126. Marson A, Burnside G, Appleton R, et al. SANAD II collaborators. The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet. 2021 Apr 10;397(10282):1363–1374. https://doi: 10.1016/S0140-6736(21)00247-6.

127. Kanner AM, Bicchi MM, et al. Antiseizure Medications for Adults with Epilepsy. Clinical Review & Education. 2022 Apr 5; 327(13):1269–1281. https://doi:10.1001/jama.2022.3880.

128. Evan F, Joiner BA, Brett E, et al. Effectiveness of perioperative antiepileptic drug prophylaxis for early and late seizures following oncologic neurosurgery: a meta-analysis. J Neurosurgery. 2018Apr 27;130(4):1274–1282. https://doi: 10.3171/2017.10.JNS172236.

129. Okudan ZV, et al. Reflex epilepsy: triggers and management strategies. J NeuropsychiatricDisease andTreatment. 2018 Jan 18;(14):327–337. https://doi:10.2147/NDT.S107669.

130. Nolan SJ, Smith CT, Weston J, et al. Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews. 2016 Nov 14;11(11):CD001031. https://doi:10.1002/14651858. CD001031.pub3.

131. Liu YT, Chen GT, Huang YC, et al. Effectiveness of dose-escalated topiramate monotherapy and add-on therapy in neurosurgery-related epilepsy. J Medicine (Baltimore). 2020 Dec. 24;99(52):e23771. https://doi:10.1097/MD.0000000000023771.

132. Rossi J, Cavallieri F, Bassi MC, et al. Efficacy and Tolerability of Perampanel in Brain Tumor-Related Epilepsy: A Systematic Review. J Biomedicines. 2023 Feb 21;11(3):651. https://doi: 10.3390/biomedicines11030651.

133. Fang S, Zhan Y, Xie YF, et al. Predictive value of electrocorticography for postoperative epilepsy in patients with supratentorial meningioma. J Clin Neurosci. 2013 Jan;20(1):112–6. https://doi: 10.1016/j.jocn.2012.02.021.

134. Ravindranath K, Vasudevan MC, Pande A, et al. Management of pediatric intracranial meningiomas: an analysis of 31 cases and review of literature. ChildsNerv. Syst. 2013 Apr;29(4):573–82. https://doi: 10.1007/s00381-012-2010-7.

135. Zheng Z, Chen P, Fu W, et al. Early and late postoperative seizure outcome in 97 patients with supratentorial meningioma and preoperative seizures: a retrospective study. J Neurooncol. 2013;(114):101–109. https://doi: 10.1007/s11060-013-1156-9.

136. Wirsching HG, Morel C, Gmür C, et al. Predicting outcome of epilepsy after meningioma resection J Neuro-Oncology. 2016;18(7):1002–1010. https://doi:10.1093/neuonc/nov303.

137. Raza SM, Gallia GL, Brem H, et al. Perioperative and long-term outcomes from the management of parasagittal meningiomas invading the superior sagittal sinus. Neurosurgery. 2010 Oct;67(4):885–93; discussion 893. https://doi:10.1227/NEU.0b01 3e3181ef2a18.

138. Alvernia JE, Dang ND, Sindou MP. Convexity meningiomas: study of recurrence factors with special emphasis on the cleavage plane in a series of 100 consecutive patients. J Neurosurg. 2011 Sep;115(3):491–8. https://doi: 10.3171/2011.4.JNS101922.

139. Tsuji M, Shinomiya S, Inoue R, et al. Prospective study of postoperative seizure in intracranial meningioma. Jpn J Psychiatry Neurol. 1993 Jun;47(2):331–4. https://doi: 10.1111/j.1440-1819.1993.tb02094.x.

140. Im SH, Wang KC, Kim SK, et al. Childhood meningioma: unusual location, atypical radiological findings, and favorable treatment outcome. ChildsNervSyst. 2001 Nov;17(11):656–62. https://doi:10.1007/s003810100507.

141. Chan RC, Thompson GB. Morbidity, mortality, and quality of life following surgery for intracranial meningiomas. A retrospective study in 257 cases. J Neurosurg. 1984 Jan;60(1):52–60. https://doi: 10.3171/jns.1984.60.1.0052.

142. Sanai N, Sughrue ME, Shangari G, et al. Risk profile associated with convexity meningioma resection in the modern neurosurgical era. J Neurosurg. 2010 May;112(5):9139. https://doi:10.3171/2009.6.JNS08149.

143. Sughrue ME, Rutkowski MJ, Chang EF, et al. Postoperative seizures following the resection of convexity meningiomas: are prophylactic anticonvulsants indicated? Clinicalarticle. J Neurosurg. 2011 Mar;114(3):705–9. https://doi:10.3171/2010.5.JNS091972.

144. North JB, Penhall RK, Hanieh A, et al. Phenytoin and postoperative epilepsy. A double-blind study. J Neurosurg. 1983 May;58(5):672–7. https://doi: 10.3171/jns.1983.58.5.0672.

145. Franceschetti S, Binelli S, Casazza M, et al. Influence of surgery and antiepileptic drugs on seizures symptomatic of cerebral tumours. ActaNeurochir. 1990;103(1–2):47–51. https://doi: 10.1007/BF01420191.

146. Forsyth PA, Weaver S, Fulton D, et al. Prophylactic anticonvulsants in patients with brain tumour. Can J NeurolSci. 2003 May;30(2):106–12. https://doi: 10.1017/s0317167100053361.

147. Ellis EM, Drumm MR, Rai SM, et al. Longterm antiseizure medication use in patients after meningioma resection: identifying predictors for successful weaning and failures. J Neurooncol. 2023 Oct;165(1):201–207. https://doi: 10.1007/s11060-023-04481-6.

148. Matthew E, Sherwin AL, Welner SA, et al. Seizures following intracranial surgery: incidence in the first postoperative week. Can J Neurol Sci. 1980 Nov;7(4):285–90. https://doi:10.1017/s0317167100022757.

149. Kvam DA, Loftus CM, Copeland B, et al. Seizures during the immediate postoperative period. Neurosurgery. 1983 Jan;12(1):14–7. https://doi:10.1227/00006123-198301000-00003.

150. Kuijlen JM, Teernstra OP, Kessels AG, et al. Effectiveness of antiepileptic prophylaxis used with supratentorial craniotomies: a metaanalysis. Seizure. 1996 Dec;5(4):291–8. https://doi:10.1016/s1059-1311(96)80023-9.

151. Telfeian AE, Philips MF, Crino PB, et al. Postoperative epilepsy in patients undergoing craniotomy for glioblastoma multiforme. J.Exp.Clin. Cancer Res. 2001 Mar;20(1):5–10.

152. Jenkinson M, Helmy A, Huckey H, et al. Surgeons Trial of Prophylaxis for Epilepsy in Seizure Naïve Patients with Meningioma: A Randomized Controlled Trial (STOP ‘Em). Neuro-Oncol. Pract. 2020. https://doi:10.1093/neuonc/noaa215.815